Dr George Follows (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) talks with Dr Andrew Zelenetz (Memorial Sloan Kettering Cancer Centre, New York, USA) at the BSH conference in Glasgow.

Comparing first line schemes between USA and UK CLL treatment, with specific regard to the recent RESONATE-2 trial of frontline ibrutinib, they discuss toxicity, cost and combination of available treatments.

This video is supported by an educational grant from Gilead.